Biotech Business - September 17, 2019
Xbrane to list on Nasdaq Stockholm
Nasdaq Stockholm’s listing committee has decided that Xbrane Biopharma AB fulfills the requirements for admission to trading of the company’s shares on the main market Nasdaq Stockholm. The first day of trading of Xbrane’s shares on Nasdaq Stockholm is expected to be Monday 23 September 2019. The last day of trading of Xbrane’s shares on […]
Financing - June 15, 2019
Ultimovacs enters the Oslo Stock Exchange
The Norwegian cancer vaccine company has raised NOK 370 million and entered the Oslo Stock Exchange on Monday 3 June 2019. Several interested parties have now become shareholders in the company, totalling approximately 1 500 shareholders, reports Oslo Cancer Cluster. “It is good for the Norwegian health industry and for Ultimovacs when national and international […]
Listing - March 22, 2019
LIDDS to evaluate a possible listing
The company will evaluate a possible listing of its shares on Nasdaq Stockholm’s Main Market during 2020 and will engage advisors to explore this potential relisting. LIDDS is in a strong growth and expansion phase with several key projects in clinical and pre-clinical phases, including the Phase IIb Liproca Depot study, the Phase I NanoZolid-docetaxel […]
Listing - September 24, 2018
Cantargia approved for listing on the main market Nasdaq Stockholm
Nasdaq Stockholm’s Listing Committee has approved the admission of Cantargia AB’s shares for trading on the main market of Nasdaq Stockholm and the first day of trading is scheduled for 25 September. The approval is subject to customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority. The shares will […]
Listing - June 12, 2017
Bonesupport announces IPO on Nasdaq Stockholm
The Board of Directors of BONESUPPORT HOLDING AB has applied for the company’s shares to be admitted to trading on Nasdaq Stockholm’s main market. Nasdaq Stockholm has approved the company’s application subject to customary conditions. The objective is to broaden the shareholder base through a new share issue of SEK 500 million to be used […]
Listing - March 29, 2017
BerGenBio announces the terms of its IPO
Further to the announcement on 8 March 2017 regarding the intention to list the shares of BerGenBio ASA on Oslo Børs and carry out an Initial Public Offering, BerGenBio announces the terms of the IPO. Subject to approval of the listing application and the successful completion of the IPO, the shares of BerGenBio are expected […]
